文献速递淋巴瘤

MiR-146b-5p调控慢性淋巴细胞白血病细胞中IL-23受体复合物的表达

MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells.
PubMed 文献 · Blood Adv · 2022-01-01

研究在224例未经治疗的Binet A期慢性淋巴细胞白血病(CLL)患者中观察到,miR-146b-5p浓度最低者至首次治疗时间(TTFT)最短。体外实验显示miR-146b-5p结合IL-12Rβ1 mRNA的3'-UTR,其下调可上调IL-12Rβ1并表达功能性IL-23R复合物,模拟CD40刺激效应;miR-146b-5p模拟物可抑制CD40L刺激后IL-23R复合物表达,并在NSG小鼠中引起肿瘤缩小。

要点

  • 224例未经治疗Binet A期CLL中,miR-146b-5p最低者至首次治疗时间最短。
  • miR-146b-5p在体外结合IL-12Rβ1 mRNA的3'-UTR区域。
  • miR-146b-5p模拟物在NSG小鼠中引起肿瘤缩小及脾脏IL-12Rβ1阳性CLL细胞减少。

核心结论

  • IL-12Rβ1表达是IL-23与IL-23R复合物环路功能的关键检查点,受miR-146b-5p调控,后者可能成为治疗靶点,因其参与CLL发病。

研究设计与样本

  • 研究纳入224例未经治疗的Binet A期CLL患者,并进行体外荧光素酶实验、miRNA抑制剂与模拟物实验及NSG小鼠移植实验;该试验注册号为NCT00917540。

主要发现

  • 224例未经治疗Binet A期患者中,miR-146b-5p浓度最低的病例至首次治疗时间(TTFT)最短。
  • 体外荧光素酶实验显示miR-146b-5p显著结合IL-12Rβ1 mRNA的3'-UTR区域。
  • 体外用特异性miRNA抑制剂下调miR-146b-5p导致IL-12Rβ1侧链上调并表达功能性IL-23R复合物,类似于通过表面CD40分子刺激CLL细胞后观察到的结果。
  • 体外用miRNA模拟物表达miR-146b-5p可抑制CD40L刺激后IL-23R复合物的表达。
  • 向成功植入CLL细胞的NSG小鼠给予miR-146b-5p模拟物引起肿瘤缩小,伴脾脏白血病结节及IL-12Rβ1阳性CLL细胞减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) cells express the interleukin-23 receptor (IL-23R) chain, but the expression of the complementary IL-12Rβ1 chain requires cell stimulation via surface CD40 molecules (and not via the B-cell receptor [BCR]). This stimulation induces the expression of a heterodimeric functional IL-23R complex and the secretion of IL-23, initiating an autocrine loop that drives leukemic cell expansion. Based on the observation in 224 untreated Binet stage A patients that the cases with the lowest miR-146b-5p concentrations had the shortest time to first treatment (TTFT), we hypothesized that miR-146b-5p could negatively regulate IL-12Rβ1 side chain expression and clonal expansion. Indeed, miR-146b-5p significantly bound to the 3'-UTR region of the IL-12Rβ1 mRNA in an in vitro luciferase assay. Downregulation of miR-146b-5p with specific miRNA inhibitors in vitro led to the upregulation of the IL-12Rβ1 side chain and expression of a functional IL-23R complex similar to that observed after stimulation of the CLL cell through the surface CD40 molecules. Expression of miR-146b-5p with miRNA mimics in vitro inhibited the expression of the IL-23R complex after stimulation with CD40L. Administration of a miR-146b-5p mimic to NSG mice, successfully engrafted with CLL cells, caused tumor shrinkage, with a reduction of leukemic nodules and of IL-12Rβ1-positive CLL cells in the spleen. Our findings indicate that IL-12Rβ1 expression, a crucial checkpoint for the functioning of the IL-23 and IL-23R complex loop, is under the control of miR-146b-5p, which may represent a potential target for therapy since it contributes to the CLL pathogenesis. This trial is registered at www.clinicaltrials.gov as NCT00917540.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Matis S, Grazia Recchia A, Colombo M, et al. MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells. Blood Adv. 2022. PMID: 35819446. doi:10.1182/bloodadvances.2021005726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。